Clinical trial data shows that burping rates vary by drug and dose: Ozempic injection (semaglutide): Burping reported in 3% of patients at the 0.5 mg dose and 1% of patients at the 1 mg dose Wegovy injection (semaglutide): Burping reported in 7% of adults at the 2.4 mg dose Mounjaro and Zepbound (tirzepatide): Burping reported in 25% of patients across doses (Source: Drugs.com) These numbers likely underestimate real-world prevalence, as sulfur burps are often underreported in clinical trials or described under broader terms like belching or eructation. Some patients avoid mentioning it to their doctors out of embarrassment, as well
Names and producers of drugs are listed
Zhou LY, Mo G, Wang S, Tang JF, Yue H, Huang LQ, Shao AJ, Guo LP (2014) [Stability analysis of reference gene based on real-time PCR in Artemisia annua under cadmium treatment]
The key is confirming that TSH and free T4 levels are in target range before starting semaglutide or other GLP-1 medications
For example, mtDNA copy number correlates with OXPHOS activity and may indicate potential sensitivity to mitochondrial inhibitors [133]